Uprosertib is a selective, orally bioavailable inhibitor of Akt (IC50s = 180, 328, and 38 nM for Akt1, Akt2, and Akt3, respectively).1 Uprosertib preferentially inhibits the proliferation of human cancer cell lines with Akt pathway activation via PI3K/PTEN mutation or loss.2 It can cause cell cycle arrest and consequent tumor growth inhibition in mice bearing either BT474 breast tumor or SK-OV-3 ovarian tumor xenografts.2
1.Pachl, F., Plattner, P., Ruprecht, B., et al.Characterization of a chemical affinity probe targeting Akt kinasesJ. Proteome Res.12(8)3792-3800(2013) 2.Dumble, M., Crouthamel, M.C., Zhang, S.Y., et al.Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitorPLoS One9(6)e100880(2014)
















